ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 210

Associations of Clinical Biomarkers with Radiographic Progression of Rheumatoid Arthritis (RA) in African Americans with Early Disease

Emma Astrike-Davis1, Rebecca Cleveland 1, Beth Jonas 1 and Leigh Callahan 1, 1Thurston Arthritis Research Center, Chapel Hill, NC

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: rheumatoid arthritis (RA) and biomarkers

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Epidemiology & Public Health Poster I: RA – ARP

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: To analyze longitudinal data from the Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis Registry (CLEAR) for the association between biomarkers including the HLA-DRB1 shared epitope (SE), anti-cyclic citrullinated peptide (CCP), and rheumatoid factors IgA and IgM (RFIgA and RFIgM) with changes in radiographic progression from study enrollment (< 2yrs disease duration) to 60-month disease duration. Cross-sectional studies have shown an association between SE, CCP, and RF and disease severity in various cohorts of patients with RA. This study seeks to determine the independent effects of these biomarkers as predictors of radiographic progression among African American patients while controlling for the effects of other comorbidities, socioeconomic factors, age, sex, and RA medication.

Methods: We analyzed data on 194 African American patients with information on biomarkers including SE, CRP, CCP, RFIgA and RFIgM as well as radiographic outcomes including erosion scores and joint space narrowing (JSN) at baseline and after 60 months of disease duration. Radiographic disease progression was determined by increase in disease scores from baseline to 60-month disease duration follow-up, and individuals with severe progression were identified as those in the top worst quintile of disease score increase (Erosion≥1; JSN≥7). Demographics, comorbidities, medications, and measures of SES were also collected at the baseline assessment. Multiple imputation was used to impute missing values. Multivariable multi-level linear and logistic regression models with study site adjusted for as a random effect were used to estimate linear coefficients (β), odds ratios (aOR) and 95% confidence intervals (CI) for disease prevalence and progression in relation to biomarkers at baseline. All models were adjusted for gender, age, BMI, number of comorbidities, cigarette smoking, disease duration at study entry, methotrexate/leflunomide (MTX/LEF) use, education level (< high school [HS] vs ≥ HS), home ownership, professional occupation, as well as simultaneous adjustment for all biomarker predictors.

Results: At baseline the mean age was 51 years, 86% were female, average RA disease duration was 14.05 months, and 64.4% patients were on MTX/LEF (Table 1).  Radiographic measures at baseline and 60 months are shown in Table 2. Beta estimates for the cross-sectional association between baseline biomarkers and baseline radiographic measures are shown in Table 3. Also in Table 3 are odds ratios for the association between baseline biomarkers of interest and severe radiographic progression. Results did not indicate an association of CCP, RF, or SE with severe radiographic progression in this cohort.

Conclusion: Our findings show modest associations between biomarkers and radiographic severity in cross-sectional analyses. However, when analyzing biomarker predictors of radiographic progression, CCP, RFIgM, RFIgA, and SE are not significantly associated with disease progression in African Americans over a 60-month disease duration with early RA. Future larger longitudinal studies are needed to confirm our results.


Emma Table 1

Baseline Characteristics


Emma Table 2

Radiographic measures


Emma Table 3

Cross-sectional and longitudinal results


Disclosure: E. Astrike-Davis, None; R. Cleveland, None; B. Jonas, None; L. Callahan, None.

To cite this abstract in AMA style:

Astrike-Davis E, Cleveland R, Jonas B, Callahan L. Associations of Clinical Biomarkers with Radiographic Progression of Rheumatoid Arthritis (RA) in African Americans with Early Disease [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/associations-of-clinical-biomarkers-with-radiographic-progression-of-rheumatoid-arthritis-ra-in-african-americans-with-early-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/associations-of-clinical-biomarkers-with-radiographic-progression-of-rheumatoid-arthritis-ra-in-african-americans-with-early-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology